Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB002.1M in Neovascular AMD
NCT03387566Phase 1Completed
- Sponsor
- Huabo Biopharm
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB002.1M in neovascular age-related macular degeneration (NVAMD) (5 arms), sponsored by Huabo Biopharm. Primary endpoint: Incidence of Adverse Effects, Dose Limiting Toxicity, and Maximum Tolerated Dose at 1 month. Started Feb 2018; status: completed.
02
Drugs
HB002.1M
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03387566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387566.